The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus

被引:12
作者
Helsley, S
Filipink, RA
Bowen, WD
Rabin, RA
Winter, JC
机构
[1] SUNY Buffalo, Sch Med & Biomed Sci, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA
[2] NIDDKD, Med Chem Lab, NIH, Bethesda, MD 20892 USA
关键词
ibogaine; drug discrimination; radioligand binding; sigma receptors; NMDA antagonists; opiate receptors;
D O I
10.1016/S0091-3057(97)00454-1
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Although the mechanism of action of ibogaine, a hallucinogen that may be useful in the treatment of addiction, remains un known, receptor binding studies suggest that ibogaine produces its effects via interactions with multiple receptor types. In addition to serotonergic receptors, which have been studied previously with respect to ibogaine, likely candidates include opiate, ate, sigma (sigma), and phencyclidine (PCP) binding sites. In an attempt to determine which of these receptor interactions are involved in the in vivo effects of ibogaine, ligands for sigma, PCP, and opiate receptors were assessed for their ability to substitute for or to antagonize the ibogaine-induced discriminative stimulus (10 mg/kg IF, 60 min presession) in Fischer-344 rats. Inter mediate levels of generalization were observed with the subtype nonselective sigma ligands 3-(3-hydroxyphenyl)-N-(1-propyl)-piperidine [(+)-3-PPP] (69.0%) and 1,3-di(2-tolyl)guanidine (DTG) (73.5%) but not with the sigma(1)-selective agents (+)-N-allylnormetazocine [(+)-SKF 10,047] and (+)-pentazocine. These findings, along with observations that ibogaine has appreciable affinity for sigma(2) receptors, suggest that these receptors may be involved in the ibogaine discriminative stimulus. With regard to opiate receptors, neither morphine, the prototypic mu agonist, nor kappa selective agonists (bremazocine,and U-50488) substituted for ibogaine. However, intermediate levels of generalization were observed with the mixed action opiates (-)-SKF 10,047 (78.9%), (+/-)-pentazocine (73.9%), nalorphine (70.4%), and diprenorphine (75.0%) indicating a potential role for opiate receptors in the ibogaine stimulus. Partial substitution was also observed with naltrexone (55.6%) but not with naloxone or the selective kappa antagonist nor-binaltorphimine (nor-BNI). These agents were largely ineffective as antagonists of the ibogaine cue, although naloxone produced a moderate but statistically significant antagonism (69.8%). In addition, naloxone produced complete antagonism of the ibogaine-appropriate responding elicited by both (-)-SKF 10,047 (19.7%) and nalorphine (25.8%), whereas the ibogaine appropriate responding produced by diprenorphine was only partially antagonized (44.4%). The latter observations taken together with the finding that both nalorphine (>100 mu M) and diprenorphine (30 mu M) have extremely low affinity for sigma(2)-receptors, suggest that the ibogaine-appropriate responding produced by these agents is not mediated by sigma(2) receptors. These findings imply that opiate effects may be involved in the ibogaine stimulus. In contrast to sigma(2) and opiate receptors, ibogaine's reported interactions with NMDA receptors do not appear to be involved in its discriminative stimulus, as neither PCP nor MK-801 produced a significant level of ibogaine appropriate responding. Thus, the present study offers evidence that unlike NMDA receptors,both sigma(2) and opiate receptors may be involved in the ibogaine discriminative stimulus. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 62 条
[1]  
Badio B, 1997, MOL PHARMACOL, V51, P1
[2]   PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF SIGMA-SITES IN DTG-INDUCED CONTRALATERAL CIRCLING IN RATS [J].
BASTIANETTO, S ;
PERRAULT, G ;
SANGER, DJ .
NEUROPHARMACOLOGY, 1995, 34 (01) :107-114
[3]  
Bowen W. D., 1996, Society for Neuroscience Abstracts, V22, P2006
[4]   IBOGAINE AND ITS CONGENERS ARE SIGMA(2) RECEPTOR-SELECTIVE LIGANDS WITH MODERATE AFFINITY [J].
BOWEN, WD ;
VILNER, BJ ;
WILLIAMS, W ;
BERTHA, CM ;
KUEHNE, ME ;
JACOBSON, AE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 279 (01) :R1-R3
[5]   Ibogaine block of the NMDA receptor: In vitro and in vivo studies [J].
Chen, K ;
Kokate, TG ;
Donevan, SD ;
Carroll, FI ;
Rogawski, MA .
NEUROPHARMACOLOGY, 1996, 35 (04) :423-431
[6]   HIGH-AFFINITY IBOGAINE BINDING TO A MU-OPIOID AGONIST SITE [J].
CODD, EE .
LIFE SCIENCES, 1995, 57 (20) :PL315-PL320
[7]  
COLPAERT FC, 1990, METHODS ASSESSING RE, P341
[8]   MECHANISMS OF ACTION OF IBOGAINE AND HARMALINE CONGENERS BASED ON RADIOLIGAND BINDING-STUDIES [J].
DEECHER, DC ;
TEITLER, M ;
SODERLUND, DM ;
BORNMANN, WG ;
KUEHNE, ME ;
GLICK, SD .
BRAIN RESEARCH, 1992, 571 (02) :242-247
[9]   THE ROLE OF THE 5-HT2A AND 5-HT2C RECEPTORS IN THE STIMULUS EFFECTS OF M-CHLOROPHENYLPIPERAZINE [J].
FIORELLA, D ;
RABIN, RA ;
WINTER, JC .
PSYCHOPHARMACOLOGY, 1995, 119 (02) :222-230
[10]   EFFECTS OF IBOGAINE ON NALOXONE-PRECIPITATED WITHDRAWAL IN MORPHINE-DEPENDENT MICE [J].
FRANCES, B ;
GOUT, R ;
CROS, J ;
ZAJAC, JM .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1992, 6 (8-9) :327-332